SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Xeris Biopharma Holdings, Inc. is a biopharmaceutical company, which engages in developing and commercializing products across a range of therapies. Its products include Gvoke, Keveyis, and Recorlev. Gvoke is a ready-to-use liquid glucagon for the treatment of severe hypoglycemia. Keveyis is the therapy approved in the United States to treat hyperkalemic, hypokalemic, and related variants of primary periodic paralysis (PPP). Recorlev is a cortisol synthesis inhibitor approved for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome. The company was founded by Steven Prestrelski in 2005 and is headquartered in Chicago, IL.

Xeris Biopharma Holdings Inc

Xeris Biopharma is trending as traders analyze the potential for future revenue growth, specifically highlighting the commercial trajectory of Recorlev and the upcoming Phase 3 trial for XP-8121. While some investors remain cautious about long-term timelines and share dilution, others view the recent debt retirement and improving operational fundamentals as strong indicators of the company's long-term value.

Rolls-Royce Holdings Plc designs, develops, manufactures, and services integrated power systems for use in the air, on land, and at sea. The company operates its business through following segments: Civil Aerospace, Power Systems, and Defense. The Civil Aerospace segment offers commercial aero engines and aftermarket services. The Power Systems segment includes engines, power systems and nuclear systems for civil power generation. The Defense segment consists of military aero engines, naval engines, submarines and aftermarket services. The company was founded in March 1906 and is headquartered in London, the United Kingdom.

Rolls-Royce Holdings Plc - ADR

Rolls-Royce is trending as investors anticipate the company's upcoming earnings report and potential announcements regarding a major hyperscaler contract for its power systems and small modular reactor technology. Market sentiment remains largely bullish, supported by strong performance across its civil aerospace and defense divisions and continued confidence in the company's ongoing turnaround and growth strategy.

Oklo, Inc. engages in the development of fission reactors. It provides clean energy through the design and deployment of fast fission power plants. The company was founded by Jacob DeWitte and Caroline Cochran on July 3, 2013 and is headquartered in Santa Clara, CA.

Oklo Inc. - Ordinary Shares - Class A

Oklo Inc.

Oklo is trending as investors digest the announcement of a new $1 billion at-the-market equity offering program, fueling widespread concerns regarding shareholder dilution. While some traders view the move as a necessary step for financing long-term infrastructure and reactor development, many express frustration over the company's capital-intensive model and continued insider selling.

Onyx is an infrastructure for a multi-asset, scalable, and cryptographically secure ledger. Onyx functions as a blockchain-based technology that enhances financial ecosystems by enabling a more efficient and interconnected economy, with a mission to develop cryptographic ledgers that optimize security, scalability, and usability. XCN is native to the Onyx XCN Ledger Blockchain as well as the Onyx Goliath Blockchain. XCN is also used as an ERC-20 token for Staking and Governance.

Onyxcoin

Onyxcoin is seeing polarized community sentiment, with some traders highlighting long-term infrastructure developments and potential neobank adoption, while many others label the asset a recurring pump-and-dump scheme. Discussion remains heavily focused on whether recent volatility and promotional activity indicate a bottoming period or continued manipulation.

Vera Therapeutics, Inc. is a clinical stage biotechnical company, which engages in the development and commercialization of transformative treatments for immunological diseases. Its product includes the TRUTAKNA injection. The company was founded by Marshall W. Fordyce in May 2016 and is headquartered in Brisbane, CA.

Vera Therapeutics Inc - Ordinary Shares - Class A

Vera Therapeutics is generating significant interest as traders await the phase 3 ORIGIN 3 eGFR clinical data, which is expected by the end of the third quarter. The conversation is dominated by bullish sentiment regarding the potential for a vertical price breakout following the readout, supported by high short interest and expectations for a major binary event.

Algorand is a scalable, secure, and decentralized digital currency and smart contract platform. Its protocol uses a variation of Proof-of-Stake (PoS) called Pure PoS (PPoS) to secure the network and reach consensus on block production. Developers can build decentralized applications (dApps) using familiar programming languages, including Python, which Algorand supports natively. Its infrastructure enables various use cases, including payment systems, digital identity solutions, supply-chain tracking, and financial services. The protocol's architecture allows for tokenization of assets and the development of smart contracts, while its technical specifications support both retail users seeking basic transaction capabilities and enterprises requiring more, complex, blockchain solutions.

Algorand

Algorand is trending as traders focus on the platform's post-quantum cryptographic roadmap and its growing utility in AI-agent initiated transactions. The community is split between bullish sentiment regarding the network's technological progress and persistent bearish skepticism centered on long-term price performance and foundation activities.

Netskope, Inc. engages in the provision of cloud-based security solutions. It offers business developing analytics for visibility, policy enforcement and other cloud solutions. Its products include Netskope one Secure Access Services Edge (SASE), Netskope one Security Service Edge (SSE), cloud access security broker, next generation secure web gateway, private access, cloud firewall, Software-Defined Wide Area Network (SD-WAN), and skopeAI. The company was founded by Sanjay Beri, Lebin Cheng, Ravishankar Ithal and Krishna Narayanaswamy in October 2012 and is headquartered in Santa Clara, CA.

Netskope Inc. - Ordinary Shares - Class A

Netskope is experiencing downward price pressure as traders speculate on the impact of new advanced AI models on traditional cybersecurity, while sentiment remains divided between those concerned about competition and others viewing the decline as an irrational buying opportunity for a SASE leader.

Fastly, Inc. provides real-time content delivery network services. It offers edge compute, edge delivery, edge security, edge applications like load balancing and image optimization, video on demand, and managed edge delivery. The company was founded by Artur Bergman, Tyler McMullen, Simon Wistow, and Gil Penchina in March 2011 and is headquartered in San Francisco, CA.

Fastly Inc - Ordinary Shares - Class A

Fastly Inc

Fastly is experiencing significant volatility and downward pressure as traders debate whether the recent post-earnings sell-off has created an attractive long-term entry point or if the stock is facing a deeper structural decline. While some market participants express frustration over persistent selling and insider activity, others view the current price as a value opportunity supported by the company's edge computing and security growth, leading to active speculation on technical support levels.

Oracle Corp. engages in the provision of products and services that address aspects of corporate information technology environments, including applications and infrastructure technologies. It operates through the following business segments: Cloud and License, Hardware, and Services. The Cloud and License segment markets, sells, and delivers enterprise applications and infrastructure technologies through cloud and on-premise deployment models including cloud services and license support offerings. The Hardware segment provides infrastructure technologies including Oracle Engineered Systems, servers, storage, industry-specific hardware, operating systems, virtualization, management, and other hardware-related software. The Services segment offers consulting, advanced support, and education services. The company was founded by Lawrence Joseph Ellison, Robert Nimrod Miner, and Edward A. Oates on June 16, 1977 and is headquartered in Austin, TX.

Oracle Corp.

Oracle shares are trending as traders debate the impact of an executive share-trading plan and the company's heavy capital expenditures on AI data centers, which have fueled both bearish concerns about debt and bullish sentiment regarding long-term revenue growth. While the stock faced selling pressure following its recent earnings report, disagreement persists over whether the move is a temporary reaction to option expiration volatility or a fundamental signal of fiscal strain.

Canadian Solar, Inc. engages in the manufacture of solar photovoltaic modules, provision of solar energy and battery storage solutions, and development of utility-scale solar and battery storage products. It operates through the CSI Solar and Global Energy segments. The CSI Solar segment designs, develops, and manufactures solar ingots, wafers, cells, modules, and other solar power and battery storage products. The Global Energy segment includes solar and battery storage project development and sale, asset management services for operational projects, sale of electricity, and investment in retained assets. The company was founded by Shawn Qu in October 2001 and is headquartered in Kitchener, Canada.

Canadian Solar Inc

Canadian Solar is trending due to investor frustration over the stock's significant undervaluation and perceived market manipulation, as many traders demand that management address the discrepancy between the company's asset value and its depressed market price. Community sentiment remains divided between those calling for a share buyback or an investigation into short-selling practices and those anticipating a potential short squeeze driven by institutional accumulation and the company's long-term growth prospects.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Washington Just Opened the Door to Psychedelic Medicine; This Microcap Already Has a Key

The war on mental illness may be entering its most dramatic turning point in a generation. On April 18, President Trump signed an Executive Order directing the FDA to accelerate research and approval pathways for psychedelic therapies including psilocybin and ibogaine, calling them a potential lifeline for Americans suffering from debilitating conditions. Six days later, the FDA followed with formal priority review designations for qualifying psychedelic treatments, signaling that this once fringe sector of biotechnology has landed squarely in the mainstream of U.S. drug policy.Shares of ...

XTLB Stock Surges 90%, Breaches 200-DMA For First Time In Over 3 Months – Here’s What The Acquisition Of Psyga Bio Brings To The Table

Equity

XTL Biopharmaceuticals announced the acquisition of Psyga Bio to gain a major foothold in the psychedelic therapeutics industry.

Wall Street’s Next Biotech Winners Emerge as FDA Acceleration Unleashes New Markets

The biotech and health-tech landscape is entering a new acceleration phase, driven by regulatory momentum, AI integration, and a surge in precision medicine.  $NEO, $TGNT, $XTLB, $SAGT, $PRCH, $AKAN

XAIR Stock More Than Doubled Today — What’s Driving The Rally?

Beyond Air said that IP portfolio company XTL will acquire 85% of its subsidiary NeuroNOS.


CommScope Stock Rockets 91% As Retail Bulls Cheer $10.5B Asset Sale: ‘Get In While It’s Cheap!’

Once the sale is completed and all financial obligations are settled, CommScope intends to return surplus funds to investors. 

XTL Biopharmaceuticals Ltd. engages in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases. Its product pipeline includes hCDR1 and rHuEPO. The company was founded on March 9, 1993 and is headquartered in Ramat Gan, Israel.

X.T.L. Biopharmaceuticals Ltd. - ADR

Neutral Sentiment

President Trump has promised to issue a $5,000 "dividend" check to every adult American citizen if the Republican Party wins control of both the House and the Senate in the upcoming midterm elections, though the proposal would require congressional approval and follows his earlier $2,000 tariff-dividend plan, which stalled after the Supreme Court struck down much of his tariff authority. Do you think the $5,000 dividend check actually happens? Vote and explain your reasoning in the comments.

Trump has pledged a $5,000 &quot;dividend&quot; check to every adult American citizen if Republicans win control of both the House and Senate in the midterms. Do you think it actually happens?

Stocktwits

Trump has pledged a $5,000 "dividend" check to every adult American citizen if Republicans win control of both the House and Senate in the midterms. Do you think it actually happens?

Feed

News

Sentiment

Fundamentals

Info

XTLB XTL Biopharmaceuticals Ltd.

Fundamentals

Latest XTLB News